Why NAD+ Declines With Age and What the Science Says About NMN
An evidence-checked research brief reviewing the Cell Metabolism review on NAD+ intermediates, the biology of age-related NAD+ decline, and the therapeutic potential of NMN and NR supplementation.
RiboCore products are supplied strictly for laboratory and in-vitro research. This page is educational and should not be read as medical advice, a diagnosis, or a recommendation for human use.
What the review covers
This summary captures the review’s scope and main conclusions. It is not an endorsement of any therapeutic application.
- NAD+ levels decline with age across multiple tissues including liver, muscle, brain, and adipose tissue. This decline is associated with impaired mitochondrial function, DNA repair, and sirtuin activity.
NAD+ is a molecule every cell needs for energy, DNA repair, and healthy aging. As you get older, your levels drop significantly across your whole body.
- NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are biosynthetic precursors that can raise tissue NAD+ levels when administered orally in preclinical models.
NMN and NR are building blocks your body can use to make more NAD+. In animal studies, taking them orally successfully raised NAD+ levels in tissues.
- Preclinical NMN supplementation improved insulin sensitivity, restored endothelial function, enhanced mitochondrial activity, and reversed age-related gene expression changes in mice.
When old mice were given NMN, their insulin sensitivity improved, blood vessels worked better, they had more endurance, and their brains were more resilient.
- The review identifies the CD38 enzyme as a major driver of age-related NAD+ decline, with CD38 expression increasing with chronic inflammation during aging.
An enzyme called CD38 increases with age-related inflammation and essentially “eats up” your NAD+. This is now considered a major reason NAD+ drops as you get older.
Evidence snapshot
NAD+ biology represents one of the most actively researched areas in longevity science, with a strong mechanistic foundation and growing translational data.
NAD+ decline is a hallmark of aging
Multiple independent groups have confirmed that tissue NAD+ levels fall 40–60% between young adulthood and old age in mammals. This decline correlates with reduced mitochondrial function, impaired DNA repair, and decreased sirtuin activity — all of which are implicated in aging.
By the time you’re old, your cells have lost 40–60% of this critical molecule. Without enough NAD+, your mitochondria slow down, DNA doesn’t get repaired properly, and your longevity genes can’t do their job.
Preclinical restoration improves healthspan
NMN supplementation in aged mice restored tissue NAD+ levels and improved multiple aging-associated phenotypes: insulin sensitivity, vascular function, physical endurance, and neuronal resilience. These results are reproducible across multiple laboratories.
When researchers gave NMN to old mice, they essentially made them metabolically younger — better insulin response, stronger blood vessels, more stamina, tougher brains.
First human NMN trial showed metabolic benefit
A 2021 clinical trial by the same group (Yoshino et al., Science) showed that 10 weeks of NMN supplementation improved muscle insulin sensitivity in prediabetic postmenopausal women — the first human evidence that NMN has tissue-specific metabolic effects.
The first human study (25 women, 10 weeks) found that NMN improved how muscles use insulin. Small study, but it’s the bridge from “works in mice” to “may work in people.”
Claim review
A useful way to read health content is to grade each major claim independently instead of accepting the whole narrative as a package.
“NAD+ supplementation reverses aging.”
NAD+ restoration improves specific age-related impairments in preclinical models and has shown one positive human metabolic endpoint. But “reversing aging” is a much broader claim that no intervention has demonstrated comprehensively.
NAD+ restoration fixes specific age-related problems in mice and showed one positive result in humans. But “reversing aging” implies comprehensive rejuvenation that no single molecule has shown.
“NAD+ declines with age.”
This is among the most reproducible findings in aging biology, confirmed across species, tissues, and laboratories. The mechanism (increased CD38 activity plus decreased biosynthesis) is well-characterized.
This is rock-solid science. Multiple labs worldwide have confirmed it across different species and tissue types. Your NAD+ drops 40–60% as you age — that’s a fact, not a claim.
“Oral NMN raises tissue NAD+ levels.”
Multiple preclinical studies and emerging human pharmacokinetic data confirm that oral NMN increases circulating and tissue NAD+ levels. The magnitude, tissue specificity, and dose-response in humans are still being characterized.
Animal data is clear, and early human data confirms it — taking NMN orally does raise NAD+ in your body. The open questions are about optimal dose, which tissues benefit most, and how long the effect lasts.
Important considerations
- Most NAD+ restoration data comes from mouse models. Mice and humans differ in NAD+ metabolism, lifespan dynamics, and disease biology.
Most of what we know comes from mice. Mouse metabolism, aging patterns, and disease biology are similar to ours but not identical.
- The first human NMN trial was small (25 women) and short (10 weeks). Large, long-duration randomized trials are needed.
The first human NMN trial involved only 25 women over 10 weeks. That’s a promising signal, not proof. We need larger studies over longer periods.
- NAD+ biology is complex: simply raising levels may not recapitulate the benefits seen in genetic or caloric restriction models.
Just raising NAD+ levels might not be enough. The benefits seen in genetic or calorie restriction studies involve complex changes that a single supplement may not replicate.
- Commercial NMN and NR products vary widely in purity, stability, and bioavailability. Quality control is a genuine concern.
Not all NMN or NR products are equal. Purity, stability, and absorption vary widely between brands. Third-party testing matters.
Research questions worth tracking
- What is the optimal dose and duration of NMN supplementation needed to sustain tissue NAD+ elevation in humans?
- Does NAD+ restoration improve clinical endpoints beyond insulin sensitivity (e.g., cardiovascular, neurological, musculoskeletal)?
- How does CD38 inhibition compare to precursor supplementation as a strategy for raising NAD+ levels?
- Are there long-term safety concerns with chronically elevated NAD+ levels, particularly regarding cellular proliferation pathways?
Primary sources
These references anchor the claims in this brief to peer-reviewed literature and authoritative guidance.
Research-use note
Nothing on this page should be used to diagnose, treat, or self-manage any medical condition. If a reader needs clinical guidance, the right next step is a licensed clinician and guideline-based care, not a research brief or a product listing.